Purpose The accumulation of sphingolipids in Fabry's disease (FD) leads to left ventricular
(LV) hypertrophy and shortened T1 in cardiac magnetic resonance (CMR). Early detection of …

Introduction Detecting early cardiac involvement in Fabry disease (FD) is important because
therapy may alter disease progression. Cardiovascular magnetic resonance (CMR) can …

Background Cardiac involvement is a major contributor of morbidity and mortality in Fabry
disease (FD). Early detection and accurate evaluation of the disease progression is …

Abstract Introduction About 50% of Fabry disease (FD) patients develop cardiac
manifestation, also known as Fabry cardiomyopathy. Beside echocardiography, cardiac …

Abstract Background Sphingolipid deposition in Fabry disease causes left ventricular (LV)
hypertrophy, of which the accurate assessment is essential. Cardiovascular magnetic …

Abstract Aims Cardiac involvement in Fabry disease (FD) occurs prior to left ventricular
hypertrophy (LVH) and is characterized by low myocardial native T1 with sphingolipid …

Aims Fabry cardiomyopathy (FC) is characterized by progressive left ventricular hypertrophy
(LVH). Conventional echocardiography is not sensitive in detecting preclinical FC before the …

Background Fabry disease (FD) is an X-linked lysosomal storage disorder leading to
intracellular accumulation of glycosphingolipid affecting multiple organs including the heart …

Background Fabry disease is characterized by a progressive deposition of sphingolipids in
different organ systems, whereby cardiac involvement leads to death. We hypothesize that …

Purpose: Detection of cardiac involvement in Fabry disease (FD) is of high importance for
treatment management. Native T1 mapping especially showed great potential for detection …